Ron Squarer Acquires Shares in Nuvalent, Inc. (NUVL)

On June 16, 2026, Ron Squarer purchased 3,444 shares of Nuvalent, Inc. (NasdaqGS: NUVL). This insider transaction did not involve a planned purchase, as indicated by the transaction code 'A'. The shares were acquired without an associated purchase price or total value disclosed.

Other Institutional Activity in Nuvalent, Inc.

Several institutional investors have been active in Nuvalent, Inc. Deerfield Management Company, L.P. held steady with 17,248,450 shares valued at approximately $1.77 billion. Meanwhile, FMR LLC reduced its position by 1,577,925 shares, ending with 9,274,959 shares worth about $950.2 million. Paradigm Biocapital Advisors LP increased its stake by 55,000 shares, bringing its total to 5,324,433 shares valued at $545.5 million. BlackRock, Inc. added 19,524 shares, totaling 4,824,785 shares valued at $494.3 million. JPMorgan Chase & Co boosted its holdings significantly by 883,098 shares, reaching a total of 3,088,349 shares worth $298.7 million.

Nuvalent, Inc. Stock Snapshot

Shares of Nuvalent, Inc. (NasdaqGS: NUVL) traded near $123.36, close to its 52-week high of $123.62. The company has a market cap of approximately $9.76 billion. Despite not being profitable, Nuvalent's forward P/E ratio is listed at -29.86, indicating expected losses. The stock's beta is 1.153, suggesting moderate volatility. It has a 50-day moving average of $105.27 and a 200-day moving average of $99.44, with strong liquidity ratios, including a current ratio of 16.14 and a quick ratio of 15.89.

Analysts Set New Price Targets

On June 10, 2026, TD Cowen, Barclays, UBS, and Guggenheim all downgraded Nuvalent to a 'hold' rating, each setting a price target of $124. Wells Fargo, HC Wainwright & Co., Wedbush, and LifeSci Capital issued similar downgrades on June 9, 2026, also setting targets at $124. The consensus among 16 analysts is a 'hold' recommendation with a mean target price of $128.13.

About Nuvalent, Inc.

Nuvalent, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing cancer therapies. The company is working on several innovative drug candidates, including Zidesamtinib, Neladalkib, and NVL-330, which target specific cancer pathways and aim to overcome treatment resistance and side effects. Led by CEO Dr. James R. Porter, Nuvalent collaborates with Guardant Health, Inc. to develop companion diagnostics.

Bottom Line

Ron Squarer's recent purchase of Nuvalent shares highlights ongoing insider interest in the company. Nuvalent, a biotechnology firm, continues to develop promising cancer treatments. The stock is trading near its 52-week high, reflecting investor optimism. However, recent analyst downgrades to 'hold' suggest a cautious outlook. As always, remember that 13F filings and insider transactions are backward-looking and may not reflect current positions.